Cell Growth of BG-1 Ovarian Cancer Cells was Promoted by 4-Tert-octylphenol and 4-Nonylphenol via Downregulation of TGF-β Receptor 2 and Upregulation of c-myc |
Park, Min-Ah
(Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University)
Hwang, Kyung-A (Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) Lee, Hye-Rim (Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) Yi, Bo-Rim (Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) Choi, Kyung-Chul (Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University) |
1 | Yilmaz, M., Maass, D., Tiwari, N., Waldmeier, L., Schmidt, P., Lehembre, F. and Christofori, G. (2011). Transcription factor Dlx2 protects from TGFbeta-induced cell-cycle arrest and apoptosis. EMBO. J., 30, 4489-4499. DOI ScienceOn |
2 | Regan, M.M., Viale, G., Mastropasqua, M.G., Maiorano, E., Golouh, R., Carbone, A., Brown, B., Suurkula, M., Langman, G., Mazzucchelli, L., Braye, S., Grigolato, P., Gelber, R.D., Castiglione- Gertsch, M., Price, K.N., Coates, A.S., Goldhirsch, A. and Gusterson, B. (2006). Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J. Natl. Cancer Inst., 98, 1571-1581. DOI ScienceOn |
3 | Schuster, N. and Krieglstein, K. (2002). Mechanisms of TGF-betamediated apoptosis. Cell Tissue Res., 307, 1-14. DOI |
4 | Shanle, E.K. and Xu, W. (2011). Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem. Res. Toxicol., 24, 6-19. DOI ScienceOn |
5 | Terasaka, S., Inoue, A., Tanji, M. and Kiyama, R. (2006). Expression profiling of estrogen-responsive genes in breast cancer cells treated with alkylphenols, chlorinated phenols, parabens, or bis- and benzoylphenols for evaluation of estrogenic activity. Toxicol. Lett., 163, 130-141. DOI ScienceOn |
6 | Theriault, B.L. and Nachtigal, M.W. (2011). Human ovarian cancer cell morphology, motility, and proliferation are differentially influenced by autocrine TGFbeta superfamily signalling. Cancer Lett., 313, 108-121. DOI ScienceOn |
7 | Watanabe, J., Kamata, Y., Seo, N., Okayasu, I. and Kuramoto, H. (2007). Stimulatory effect of estrogen on the growth of endometrial cancer cells is regulated by cell-cycle regulators. J. Steroid. Biochem. Mol. Biol., 107, 163-171. DOI ScienceOn |
8 | Yi, B.R., Kang, N.H., Hwang, K.A., Kim, S.U., Jung, E.B. and Choi, K.C. (2011). Antitumor Therapeuic Effects of Cytosinf Deaminase and Interferon-â Against Endometrial Cancer Cells Using Genetically Ebngineered Stem Cells In Vitro. Anticancer Reserch, 31, 2853-2861. |
9 | McCaffrey, T.A., Consigli, S., Du, B., Falcone, D.J., Sanborn, T.A., Spokojny, A.M. and Bush, H.L., Jr. (1995). Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J. Clin. Invest., 96, 2667-2675. DOI ScienceOn |
10 | Nilsson, E.E. and Skinner, M.K. (2002). Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. Reprod. Biomed. Online, 5, 254-258. DOI ScienceOn |
11 | Pedram, A., Razandi, M. and Levin, E.R. (2006). Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol., 20, 1996-2009. DOI ScienceOn |
12 | Osada, H., Yoshitake, Y., Ikeda, T., Ishigaki, Y., Takata, T., Tomosugi, N., Sasaki, H. and Yonekura, H. (2011). Ultraviolet Binduced expression of amphiregulin and growth differentiation factor 15 in human lens epithelial cells. Mol. Vis., 17, 159-169. |
13 | Park, M.A., Hwang, K.A., Lee, H.R., Yi, B.R., Jeung, E.B. and Choi, K.C. (2011). Cell growth of BG-1 ovarian cancer cells was promoted by di-n-butyl phthalate and hexaboromocyclododecane via upregulation of cyclin D and cell cycle-dependent kinase-4 genes. Mol. Med. Report. In press. |
14 | Park, S.H., Kim, K.Y., An, B.S., Choi, J.H., Jeung, E.B., Leung, P.C. and Choi, K.C. (2009). Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38. J. Reprod. Dev., 55, 23-29. DOI ScienceOn |
15 | Hwang, K.A., Park, S.H., Yi, B.R. and Choi, K.C. (2011). Gene alterations of ovarian cancer cells expressing estrogen receptors by estrogen and bisphenol a using microarray analysis. Lab. Anim. Res., 27, 99-107. DOI |
16 | Ito, I., Hanyu, A., Wayama, M., Goto, N., Katsuno, Y., Kawasaki, S., Nakajima, Y., Kajiro, M., Komatsu, Y., Fujimura, A., Hirota, R., Murayama, A., Kimura, K., Imamura, T. and Yanagisawa, J. (2010). Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J. Biol. Chem., 285, 14747-14755. DOI ScienceOn |
17 | Khan, S.A., Rogers, M.A., Khurana, K.K., Meguid, M.M. and Numann, P.J. (1998). Estrogen receptor expression in benign breast epithelium and breast cancer risk. J. Natl. Cancer Inst., 90, 37-42. DOI ScienceOn |
18 | Massague, J., Seoane, J. and Wotton, D. (2005). Smad transcription factors. Genes. Dev., 19, 2783-2810. DOI ScienceOn |
19 | Kim, D.Y., Kim, M.J., Kim, H.B., Lee, J.W., Bae, J.H., Kim, D.W., Kang, C.D. and Kim, S.H. (2011). Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim. Biophys. Acta., 1812, 796-805. DOI ScienceOn |
20 | Kochukov, M.Y., Jeng, Y.J. and Watson, C.S. (2009). Alkylphenol xenoestrogens with varying carbon chain lengths differentially and potently activate signaling and functional responses in GH3/B6/F10 somatomammotropes. Environ Health Perspect., 117, 723-730. DOI ScienceOn |
21 | Massague, J. (2008). TGFbeta in Cancer. Cell, 134, 215-230. DOI ScienceOn |
22 | Matsuda, T., Yamamoto, T., Muraguchi, A. and Saatcioglu, F. (2001). Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J. Biol. Chem., 276, 42908-42914. DOI ScienceOn |
23 | Dunfield, L.D. and Nachtigal, M.W. (2003). Inhibition of the antiproliferative effect of TGFbeta by EGF in primary human ovarian cancer cells. Oncogene, 22, 4745-4751. DOI ScienceOn |
24 | Elliott, R.L. and Blobe, G.C. (2005). Role of transforming growth factor Beta in human cancer. J. Clin. Oncol., 23, 2078-2093. DOI ScienceOn |
25 | Feng, X.H. and Derynck, R. (2005). Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol., 21, 659-693. DOI ScienceOn |
26 | Hagiwara, H., Sugizaki, T., Tsukamoto, Y., Senoh, E., Goto, T. and Ishihara, Y. (2008). Effects of alkylphenols on bone metabolism in vivo and in vitro. Toxicol. Lett., 181, 13-18. DOI ScienceOn |
27 | Gantus, M.A., Alves, L.M., Stipursky, J., Souza, E.C., Teodoro, A.J., Alves, T.R., Carvalho, D.P., Martinez, A.M., Gomes, F.C. and Nasciutti, L.E. (2011). Estradiol modulates TGF-beta1 expression and its signaling pathway in thyroid stromal cells. Mol. Cell Endocrinol., 337, 71-79. DOI ScienceOn |
28 | Gomis, R.R., Alarcon, C., Nadal, C., Van Poznak, C. and Massague, J. (2006). C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell, 10, 203-214. DOI ScienceOn |
29 | Goto, N., Hiyoshi, H., Ito, I., Tsuchiya, M., Nakajima, Y. and Yanagisawa, J. (2011). Estrogen and antiestrogens alter breast cancer invasiveness by modulating the transforming growth factor-beta signaling pathway. Cancer Sci., 102, 1501-1508. DOI ScienceOn |
30 | Hill, J.J., Tremblay, T.L., Cantin, C., O'Connor-McCourt, M., Kelly, J.F. and Lenferink, A.E. (2009). Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transition. Proteome. Sci., 7, 2. DOI ScienceOn |
31 | Asimakopoulos, A.G., Thomaidis, N.S. and Koupparis, M.A. (2011). Recent trends in biomonitoring of bisphenol A, 4-toctylphenol, and 4-nonylphenol. Toxicol. Lett. In press. |
32 | Choi, S.M., Yoo, S.D. and Lee, B.M. (2004). Toxicological characteristics of endocrine-disrupting chemicals: developmental toxicity, carcinogenicity, and mutagenicity. J. Toxicol. Environ. Health B Crit. Rev., 7, 1-24. DOI |
33 | Band, A.M. and Laiho, M. (2011). Crosstalk of TGF-beta and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia, 16, 109-115. DOI |
34 | Chen, C.R., Kang, Y., Siegel, P.M. and Massague, J. (2002). E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell, 110, 19-32. DOI ScienceOn |
35 | Choi, K.C. and Jeung, E.B. (2003). The biomarker and endocrine disruptors in mammals. J. Reprod. Dev., 49, 337-345. DOI ScienceOn |
36 | Diamanti-Kandarakis, E., Bourguignon, J.P., Giudice, L.C., Hauser, R., Prins, G.S., Soto, A.M., Zoeller, R.T. and Gore, A.C. (2009). Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev., 30, 293-342. DOI ScienceOn |
37 | Doisneau-Sixou, S.F., Sergio, C.M., Carroll, J.S., Hui, R., Musgrove, E.A. and Sutherland, R.L. (2003). Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer, 10, 179-186. DOI |